Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an update.
On February 5, 2026, Ascentage Pharma announced that its next-generation Bruton’s tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) clearance from China’s Center for Drug Evaluation, shortly after securing a similar clearance from the U.S. Food and Drug Administration. The company now plans a multicenter, open-label Phase I trial in patients with relapsed or refractory hematologic malignancies to assess safety, tolerability, pharmacokinetics and preliminary efficacy, positioning APG-3288 as a potential new option for patients who have developed resistance to existing BTK inhibitors. By using PROTAC technology to degrade both wild-type and mutant BTK rather than merely inhibit it, APG-3288 could help address significant unmet needs in B-cell malignancies and further strengthen Ascentage Pharma’s hematology-focused pipeline, while reinforcing its global ambitions in targeted protein degradation and combination therapy strategies.
The most recent analyst rating on (AAPG) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Neutral.
The score is primarily held back by weak financial quality (ongoing losses, negative cash flow, and high leverage risk) and bearish technical conditions (negative MACD and price below key moving averages). Rapid revenue growth provides some offset, but valuation signals are limited due to negative earnings and no dividend data.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage, integrated biopharmaceutical company focused on discovering, developing and commercializing novel, differentiated therapies for cancer, particularly hematologic malignancies. Its pipeline spans apoptotic pathway inhibitors targeting proteins such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders, and includes two approved products in China: Olverembatinib, a third-generation BCR-ABL1 inhibitor for various forms of chronic myeloid leukemia, and Lisaftoclax, a Bcl-2 inhibitor for previously treated CLL/SLL. The company is pursuing multiple global registrational Phase III trials and collaborates with major pharmaceutical companies and leading research institutions worldwide.
Average Trading Volume: 4,222
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.27B
See more data about AAPG stock on TipRanks’ Stock Analysis page.